Equity Overview
Price & Market Data
Price: $7.64
Daily Change: +$0.61 / 7.98%
Daily Range: $6.92 - $8.00
Market Cap: $1,693,642,112
Daily Volume: 13,003,422
Performance Metrics
1 Week: -14.13%
1 Month: -31.87%
3 Months: -33.84%
6 Months: -34.95%
1 Year: 7.31%
YTD: -35.91%
Company Details
Employees: 325
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.